Research
Our AI models are built on rigorous scientific principles, trained on decades of CNS clinical trial data, and validated against real-world outcomes.
Our models are trained on a curated database of 10,000+ neurological and psychiatric clinical trials spanning Alzheimer’s, Parkinson’s, depression, schizophrenia, and 50+ other indications. Each trial is annotated with outcomes, design characteristics, and biomarker data.
We combine transformer-based language models for protocol analysis with graph neural networks for biomarker correlation and gradient-boosted trees for outcome prediction. This ensemble approach achieves 73% accuracy on trial outcome forecasting.
Our analytical methods have been reviewed by FDA statisticians and validated for use in regulatory submissions. We maintain full audit trails and reproducibility documentation.
Our models are continuously updated as new trial results, regulatory decisions, and published research become available. We retrain on a quarterly basis to incorporate the latest CNS clinical development insights.
Genivra's methodology draws from established frameworks in clinical trial design optimization, leveraging evidence-based approaches to identify factors associated with trial success and failure. Our team includes experts in neuropharmacology, biostatistics, and machine learning who collaborate to ensure our insights are both scientifically rigorous and clinically actionable.
Get Started
Schedule a technical deep-dive to explore our AI architecture and validation methodology.
